Amgen today announced the appointment of Esteban Santos as executive vice president, Operations, effective July 25, 2016, reporting to Robert A. Bradway, chairman and chief executive officer.
Santos will be responsible for Amgen’s Operations organization which encompasses manufacturing, process development, quality, engineering and global supply chain. He will succeed Madhavan (Madhu) Balachandran, 65, who is retiring at the end of the year.
Santos, 48, has been senior vice president, Manufacturing with responsibilities for worldwide product supply since 2013. He joined Amgen in 2007 and previously held various leadership roles, including vice president, Drug Product; vice president, Site Operations; vice president, Manufacturing; and vice president, Engineering.
Before joining Amgen, Santos was site general manager for the Johnson & Johnson (J&J) Cordis operation in Puerto Rico. Prior to J&J, Santos held several management positions in General Electric’s industrial and transportation businesses in Puerto Rico, Connecticut, and Pennsylvania. Santos holds a bachelor of science degree in electrical engineering from the University of Puerto Rico – Mayagüez and a master of science in management from the Rensselaer Polytechnic Institute, Hartford, Connecticut.
Bradway said, “Esteban is a talented leader with a proven track record. I’m confident that Esteban and our Operations team will maintain our track record of industry-leading performance in serving ‘every patient, every time’ as we expand globally, launch new products and introduce our next-generation of biomanufacturing technologies.”
Succeeding Santos as senior vice president, Manufacturing will be Robert Maroney, who is currently vice president, Site Operations at Amgen Manufacturing, Ltd. in Juncos, Puerto Rico.
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.